Travere officer may sell $353K in stock

An officer of Travere Therapeutics filed a Rule 144 notice covering 5,375 common shares tied to a cash exercise of stock options.

Available on EDGAR 09/15/2026 - 04:45 PM EDT Accepted by SEC EDGAR 09/15/2026 - 04:44 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Travere Therapeutics, Inc. (TVTX) has a notice under Rule 144 indicating that officer Sandra Calvin may sell up to 5,375 shares of Travere common stock. The shares are associated with an exercise of stock options for cash and are to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate value of $353,621.25 as of September 15, 2026 on NASDAQ.

Key Figures

Shares covered by notice: 5,375 shares Aggregate value of shares: $353,621.25 SEC file number: 001-36257 +1 more

4 metrics

Shares covered by notice 5,375 shares Common stock referenced in the Rule 144 securities information and securities-to-be-sold sections

Aggregate value of shares $353,621.25 Aggregate value associated with the 5,375 common shares as of September 15, 2026

SEC file number 001-36257 Travere Therapeutics, Inc. SEC file number

Proposed sale date September 15, 2026 Date tied to the securities information and securities to be sold

Key Terms

Rule 144, Exercise of Stock Options, securities to be sold

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Exercise of Stock Options financial

"Common | 09/15/2026 | Exercise of Stock Options | Issuer"

securities to be sold regulatory

"Information is to be given not only as to the person for whose account the securities are to be sold"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for TVTX disclose about potential share sales?

It discloses that officer Sandra Calvin may sell up to 5,375 shares of Travere Therapeutics common stock, related to a cash exercise of stock options, with an aggregate value of $353,621.25 as of September 15, 2026.

How many Travere Therapeutics (TVTX) shares are covered by Sandra Calvin’s Rule 144 notice?

The notice covers up to 5,375 shares of Travere Therapeutics common stock, listed in the securities information and securities-to-be-sold sections of the Form 144.

What is the stated value of the TVTX shares in this Form 144 filing?

The filing lists an aggregate value of $353,621.25 for the 5,375 Travere Therapeutics common shares referenced in the Rule 144 notice, as of September 15, 2026.

What is the source of the Travere Therapeutics (TVTX) shares in this Form 144?

The Form 144 states the shares are to be sold following an Exercise of Stock Options, with the transaction type described as “Exercise of Stock Options” and payment type listed as Cash.

Through which broker are the TVTX shares in this Form 144 planned to be sold?

The common shares are associated with Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004, as the broker in the securities information section.

On which market is the Travere Therapeutics (TVTX) stock in this Form 144 listed?

The Form 144 identifies the common stock as traded on NASDAQ, with the relevant securities information dated September 15, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001882909
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	TRAVERE THERAPEUTICS, INC.
SEC File Number	001-36257
Address of Issuer	3611 Valley Centre Drive, Suite 300 San Diego CALIFORNIA 92130
Phone	8889697879
Name of Person for Whose Account the Securities are To Be Sold	SANDRA CALVIN
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	5375	353621.25	94261082	09/15/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/15/2026	Exercise of Stock Options	Issuer			5375	09/15/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	09/15/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/16/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Sandra Calvin
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)